HCW Biologics Inc. (HCWB) company profile
Close on Nov 18, 2026Market cap $1.40MP/E –Yield –
About HCW Biologics
Pharmaceutical Preparations, SIC 2834
HCW Biologics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel fusion immunotherapeutics to treat conditions driven by chronic inflammation. Its pipeline targets autoimmune and proinflammatory diseases, cancer, and senescence-associated dysplasia. The company designs its product candidates using two proprietary platforms, TOBI and TRBC. Its lead clinical candidate, HCW9302, is an injectable fusion protein complex being evaluated for alopecia areata. HCW Biologics also develops commercial-ready reagent molecules, including HCW9201 and HCW9206, which serve biopharmaceutical customers producing CAR-T and natural killer cell therapies for cancer and infectious diseases.
Operationally, the company conducts its early clinical trials across two active clinical trial sites located at The Ohio State University and the James A. Haley Veterans' Hospital. In addition, the firm partners with Beijing Trimmune Biotech Co., Ltd., which holds licensing rights to advance candidate therapies in China and retains worldwide rights for another program. The company's clinical activities and trials are based in the United States.
Summary of the business section of HCW Biologics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- HCW Biologics Inc.
- Headquarters
- Miramar, FL
- Address
- 2929 N Commerce Pkwy 33025
- Phone
- (954) 842-2024
- Website
- hcwbiologics.com
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Crowe LLP, Indianapolis, Indiana
Stock & identifiers
- Ticker
- HCWB
- Exchange
- Nasdaq
- IPO date
- Jul 21, 2021
- Shares outstanding
- 2M, Aug 12, 2026
- Public float
- $6.20M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Stock splits
- 1-for-6 reverse, Jun 30, 2026; 1-for-40 reverse, Aug 18, 2025; 1-for-40 reverse, Apr 11, 2025
- SEC CIK
- 1828673
- CUSIP
- 40423R303
- ISIN
- US40423R3030
- FIGI
- BBG011769443
- Share class FIGI
- BBG0117694Z9
- LEI
- 5299008ZJ4RXXTN04Z97
- EIN
- 82-5024477
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Hing C. Wong | Chief Executive Officer, Director | 125,845 |
| Lee Flowers | SVP of Business Development | 8,691 |
| Rebecca Byam | Chief Financial Officer | 57,245 |
| Scott T. Garrett | Director | 67,149 |
| Gary M. Winer | Director | 4,075 |
| Rick S. Greene | Director | 2,066 |
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jul 21, 2021
- Offer price
- $8.00
- Securities offered
- 7,000,000
- Gross proceeds
- $56.00M
- Exchange
- Nasdaq
- First trading day
- Jul 20, 2021
- First-day close
- $6.30-21.3%
- Lock-up ends (est.)
- Jan 16, 2022
“The initial public offering price is $8.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Corporate history
Events identified from SEC filings
See a number that looks wrong?